1378318-49-0

Basic information

• Product Name: 9-(4-fluorophenyl)-6-hydroxy-3-fluorone
• Synonyms: 9-(4-fluorophenyl)-6-hydroxy-3-fluorone
• CAS NO: 1378318-49-0
• Molecular Weight: 306.293
• Mol File: 1378318-49-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 9-(4-fluorophenyl)-6-hydroxy-3-fluorone(CAS DataBase Reference)
• NIST Chemistry Reference: 9-(4-fluorophenyl)-6-hydroxy-3-fluorone(1378318-49-0)
• EPA Substance Registry System: 9-(4-fluorophenyl)-6-hydroxy-3-fluorone(1378318-49-0)

Safety Data

• Hazardous Substances Data: 1378318-49-0(Hazardous Substances Data)

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 108-46-3 recorcinol 
• 1378318-45-6 bis(2,4-dimethoxyphenyl)-4-fluorophenyl methanol 
• 403-33-8 methyl 4-flurobenzoate 
• 17715-69-4 1-Bromo-2,4-dimethoxybenzene 

Downstream Products

• 1378318-62-7 2,5-di-(1,3,2-dithiarsolan-2-yl)-9-(4-fluorophenyl)-6-hydroxy-3-fluorone 
• 1378318-64-9 2,5-di-(1,3,2-dithiarsolan-2yl)-9(4-fluorophenyl)-6-methoxy-3-fluorone 
• 1378318-66-1 2,5-di-(1,3,2-dithiarsolan-2yl)-9(4-fluorophenyl)-6[13C₂H₃]methoxy-3-fluorone 
• 1378318-69-4 2,5-di-(1,3,2-dithiarsolan-2yl)-9(4-fluorophenyl)-6[14C]methoxy-3-fluorone 
• 1378318-70-7 2,5-di-(1,3,2-dithiarsolan-2yl)-9(4-fluorophenyl)-6-14Cmethoxy-3-fluorone 

Relevant articles and documents

A Synthetic Hybrid Molecule for the Selective Removal of Human Pluripotent Stem Cells from Cell Mixtures

A major hurdle in stem cell therapy is the tumorigenic risk of residual undifferentiated stem cells. This report describes the design and evaluation of synthetic hybrid molecules that efficiently reduce the number of human induced pluripotent stem cells (hiPSCs) in cell mixtures. The design takes advantage of Kyoto probe 1 (KP-1), a fluorescent chemical probe for hiPSCs, and clinically used anticancer drugs. Among the KP-1–drug conjugates we synthesized, we found an exceptionally selective, chemically tractable molecule that induced the death of hiPSCs. Mechanistic analysis suggested that the high selectivity originates from the synergistic combination of transporter-mediated efflux and the cytotoxicity mode of action. The present study offers a chemical and mechanistic rationale for designing selective, safe, and simple reagents for the preparation of non-tumorigenic clinical samples.

AGENTS AND METHODS FOR VISUALISING ANALYTES

Provided herein are novel compounds based on xanthene, for example biarsenical compounds, which are useful as molecular probes. The compounds contain at least one isotope atom, such as a radioisotope atom. Methods for visualizing tetracysteine-tagged analyte molecules such as proteins using said compounds, methods for synthesizing said compounds, and methods for treating cancer or other hyperproliferative disorders using said compounds are also provided.